Still not profitable yet involved in multiple patent lawsuits, Yifang Bio claims that it is not involved in the research pipeline.
① Yifang Biotechnology and its controlling person are involved in a patent infringement lawsuit, being asked to pay 99 million yuan. Yifang Biotechnology's revenue for the first three quarters of 2024 is less than 20 million yuan, and it has not yet achieved profitability; ② Company personnel stated that the lawsuit targets some patents related to Yifang Biotechnology's intellectual property and does not involve the research pipeline.
Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.
There is gain in loss.
Baillie Gifford Sheng Hong has been heard by the Hong Kong Stock Exchange for its listing application, and the sponsor has received the relevant letter.
SiChuan Baili Tianheng Pharmaceutical (688506.SH) announced that the company is applying to issue Listed in Hong Kong shares and is engaged in related work for listing on the Main Board of the Hong Kong Stock Exchange.
Breaking! 17.5 billion Zhipu AI Concept stocks are under investigation by the Securities Regulatory Commission | Evening announcement collection.
Guangxi Xinxunda Technology Group: The company and its actual controller Wu Chenghua received the "Notice of Case Filing" from the China Securities Regulatory Commission.
A total scale of 30 billion! The first national-level mother fund in the foreign trade and economic field is being raised, introducing listed company LP Jinbo Bio and Joinn Laboratories.
① The Innovation and Development Guidance Fund for Service Trade is a national-level fund initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, approved by the State Council, with a total scale of 30 billion yuan. ② An IR practitioner stated to the Star Daily that the second phase of the service trade fund inviting listed companies to become LPs may be a more market-oriented signal.
When will Hunan Nucien Pharmaceutical Co., Ltd. emerge from the shadow of losses after the termination and delay of core Innovative Drugs projects?
① Due to the difficulty of research and development and the slow progress, Hunan Nucien Pharmaceutical Co., Ltd. has terminated the development of the Peramivir dry powder inhaler project. At the same time, due to stricter approval processes, the Peramivir inhalation solution project will be postponed for two years. ② Given the multiple competition faced by the Peramivir injection, the adjustments to the new drug project will bring new uncertainties to the development of Hunan Nucien Pharmaceutical Co., Ltd.